At PrecisionLife we’re working with leading CROs, diagnostics and pharmaceutical companies to provide better tools for stratification of patient sub-groups based on a deeper understanding of disease biology.
Our high resolution patient stratification supports selection of targets that are more likely to exhibit better efficacy in phase III trials, and recruitment of smaller and more accurately targeted clinical trials populations. It also enables development of highly predictive proprietary content that can be used as the basis of novel diagnostic and theranostic tests.